Samsung Pharm (001360) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.013x

Based on the latest financial reports, Samsung Pharm (001360) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.29 Billion ≈ $-1.55 Million USD) by net assets (₩180.09 Billion ≈ $122.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Samsung Pharm (001360) strategic asset index to assess the company's strategic physical and investment asset allocation.

Samsung Pharm - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Samsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. See 001360 net assets for net asset value and shareholders' equity analysis.

Samsung Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Samsung Pharm ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Smith Douglas Homes Corp. NYSE:SDHC	0.001x
Nahar Spinning Mills Limited NSE:NAHARSPING	0.216x
SA Catana Group PA:CATG	0.120x
Genic Co. Ltd KQ:123330	0.187x
CVC Income & Growth Limited LSE:CVCE	0.023x
G J Steel Public Company Limited BK:GJS	0.040x
Multicampus Corporation KQ:067280	0.038x
Hites S.A. SN:HITES	0.142x

Annual Cash Flow Conversion Efficiency for Samsung Pharm (2012–2024)

The table below shows the annual cash flow conversion efficiency of Samsung Pharm from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Samsung Pharm (001360) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩105.86 Billion ≈ $71.74 Million	₩-17.30 Billion ≈ $-11.72 Million	-0.163x	+54.17%
2023-12-31	₩77.58 Billion ≈ $52.58 Million	₩-27.66 Billion ≈ $-18.74 Million	-0.356x	-1810.44%
2022-12-31	₩102.59 Billion ≈ $69.52 Million	₩-1.91 Billion ≈ $-1.30 Million	-0.019x	+66.85%
2021-12-31	₩127.27 Billion ≈ $86.25 Million	₩-7.16 Billion ≈ $-4.85 Million	-0.056x	-168.73%
2020-12-31	₩121.92 Billion ≈ $82.62 Million	₩-2.55 Billion ≈ $-1.73 Million	-0.021x	-22.88%
2019-12-31	₩142.83 Billion ≈ $96.79 Million	₩-2.43 Billion ≈ $-1.65 Million	-0.017x	+65.59%
2018-12-31	₩131.66 Billion ≈ $89.23 Million	₩-6.52 Billion ≈ $-4.42 Million	-0.050x	-190.23%
2017-12-31	₩93.87 Billion ≈ $63.61 Million	₩5.15 Billion ≈ $3.49 Million	0.055x	+145.48%
2016-12-31	₩82.38 Billion ≈ $55.83 Million	₩-9.94 Billion ≈ $-6.74 Million	-0.121x	-32.70%
2015-12-31	₩46.24 Billion ≈ $31.33 Million	₩-4.20 Billion ≈ $-2.85 Million	-0.091x	+84.40%
2014-12-31	₩23.29 Billion ≈ $15.79 Million	₩-13.58 Billion ≈ $-9.21 Million	-0.583x	-81.92%
2012-12-31	₩34.71 Billion ≈ $23.52 Million	₩-11.13 Billion ≈ $-7.54 Million	-0.321x	--

About Samsung Pharm

KO:001360 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$103.33 Million

₩152.47 Billion KRW

Market Cap Rank

#19167 Global

#985 in Korea

Share Price

₩1620.00

Change (1 day)

+0.00%

52-Week Range

₩1343.00 - ₩2210.00

All Time High

₩12289.83